← All indications
Mood Disorders
Those disorders that have a disturbance in mood as their predominant feature.
Subtype terms (3)
More specific conditions that are subtypes of Mood Disorders in the MeSH hierarchy.
- Bipolar and Related Disorders
2 drugs (1 approved, 1 experimental)
- Cyclothymic Disorder
- Depressive Disorder
131 drugs (86 approved, 45 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (15)
Phase 3 trials (8)
Phase 2 trials (18)
Phase 1 trials (11)
Other trials (35)
- maltodextrin
- progesterone
- escitalopram
- hypericum perforatum
- prazosin
- nicotine
- caffeine
- prucalopride succinate
- scopolamine
- sorbitol
- testosterone
- carvedilol
- bifidobacterium bifidum
- bifidobacterium longum
- biotin
- blueberry allergenic extract
- curcumin
- l-epigallocatechin
- hops extract
- lactobacillus plantarum
- aripiprazole
- midazolam
- estrogen
- turmeric
- vinegar
- loperamide
- saffron
- lactobacillus casei
- bifidobacterium lactis
- lactococcus lactis
- +5 more
Organizations
Organization Involved with Phase 4 Indications (32)
- Abbott
- Takeda
- AstraZeneca
- Otsuka
- National Institutes of Health (NIH)
- National Institute of Mental Health (NIMH)
- Region Syddanmark
- Aarhus University
- University of Pittsburgh
- Chang Gung University
- University of London
- Harvard University
- Duke University
- Federal University of Rio Grande do Sul
- Medical College of Wisconsin
- Monash University
- Stanford University
- University of Ghana
- University of Michigan
- University of South Florida
- Columbia University
- Joliet Center for Clinical Research
- University of California, San Diego
- University of Copenhagen
- Vanderbilt University
- All India Institute of Medical Sciences
- Taipei Veteran General hospital
- Government of Pakistan
- Department of Veteran Affairs
- JayMac Pharmaceuticals, LLC
- +2 more
Organization Involved with Phase 3 Indications (24)
- Pfizer
- Cognitive Research Corporation
- GlaxoSmithKline
- National Center for Complementary and Integrative Health (NCCIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Mental Health and Neuro Sciences, India
- National Institute of Neurological Disorders and Stroke (NINDS)
- Alexandria University
- Baylor University
- Case Western Reserve University
- Dow University of Health Sciences
- Federal University of Health Science of Porto Alegre
- University of Washington
- Stanley Medical Research Institute
- University of Manchester
- University of Southern California
- University of Cincinnati
- University of Sao Paulo
- Office of Dietary Supplements (ODS)
- Abbasi Shaheed Hospital
- Rawalpindi Medical College, Pakistan
- Lundbeck
- Johnson and Johnson
- BioXcel Therapeutics Inc
Organization Involved with Phase 2 Indications (28)
- Novo Nordisk
- BioLineRx, Ltd.
- Braeburn Pharmaceuticals
- Marinus Pharmaceuticals
- Columbia Northwest Pharmaceuticals
- National Institute on Drug Abuse (NIDA)
- Brown University
- Mclean Hospital
- New York University
- University of Nebraska
- University of South Carolina
- University of Toronto
- University of Vermont
- Tel Aviv University
- Uppsala University
- Medical University of South Carolina
- Icahn School of Medicine at Mount Sinai
- Food and Drug Administration
- Department of Defense
- University of Oxford
- University of Texas at Houston
- Max Planck Institute
- University of North Carolina at Chapel Hill
- Northwest Clinical Research Center
- Artemis Institute for Clinical Research
- University of Massachusetts
- National Health and Medical Research Council, Australia
- Foundation of Hope, North Carolina
Organization Involved with Phase 1 Indications (11)
Organization Involved with Other Experimental Indications (8)